Perrigo: 3 Key Takeaways for Long-Term Investors
Retailers are ordering cautiously, yet Perrigo's European health brands grew well ahead of their categories and took share.
Perrigo announced plans to sell its infant formula business during its third-quarter 2026 earnings call on November 4, 2026. The divestment aims to streamline the company's portfolio, focus on high-return self-care products, and improve overall margin profile. Interim President and CEO Albert Manzone highlighted three key takeaways for long-term investors.
Firstly, the sale will reduce capital expenditures and enhance the operating margin, allowing the company to concentrate its resources on products with the highest potential for growth. Secondly, Perrigo sees an opportunity in online shopping, which is outpacing the growth of physical retail. The company currently holds a higher market share in e-commerce than in offline stores, with U.S. e-commerce category volume increasing nearly 15% year to date and now representing 22% of its U.S. volume.
Thirdly, retailers' conservatively ordered over-the-counter products before the cold season, but Perrigo managed to gain market share in store brands and European health products, with U.S. store brand OTC volume growing 2% and 30 basis points of share, while European value sales in key brands grew 6.5% and gained 80 basis points of share.
While Perrigo remains cautious about the uncertain consumer environment, Manzone is confident that the company's actions position it to exit 2026 as a simpler and more focused consumer self-care company, led by its efficiency program, store-brand retail partnerships, and digital scale.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
